320 SOQUEL WAY, SUNNYVALE, CA
University of Wisconsin Enrolls Their First Patient in Phase 3 CardiAMP HF II Cell Therapy Pivotal Trial
Shareholder Director Nominations
Regains Compliance with Nasdaq Listing Requirements
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Announces Positive Preliminary Clinical Consultation with Japan Pharmaceutical and Medical Device Agency on Cell Therapy for Ischemic Heart Failure
News, Securities Holder Rights or Indentures
Announces Pricing of Up To $12 Million Public Offering
BioCardia Reports Positive CardiAMP Trial Results
Amended Quarterly Report
Q2
Q1
FY 2024
Q3
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(4)
Effectiveness Notice
Amended Registration Statement for Securities
S-1
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload